INVISION - An Observational Study to Explore Effectiveness, Tolerability and Safety of Paliperidone ER in Patients With Schizophrenia
- First Posted Date
- 2008-06-16
- Last Posted Date
- 2014-04-28
- Lead Sponsor
- Janssen-Cilag B.V.
- Target Recruit Count
- 27
- Registration Number
- NCT00697658
The Effect of Epoetin Alfa on Cardiac Function and Quality of Life in Patients With Early Renal ((Kidney) Disease
Phase 3
Completed
- Conditions
- First Posted Date
- 2007-03-13
- Last Posted Date
- 2011-02-01
- Lead Sponsor
- Janssen-Cilag B.V.
- Target Recruit Count
- 176
- Registration Number
- NCT00446576
VALEO: A Post Authorization Study, Designed to Learn More About the Safety and Effectiveness of the Use of Bortezomib in the Netherlands
- First Posted Date
- 2007-02-27
- Last Posted Date
- 2014-01-14
- Lead Sponsor
- Janssen-Cilag B.V.
- Target Recruit Count
- 331
- Registration Number
- NCT00440765
ADVANCE: An Observational Study To Determine Bortezomib Safety and Effectiveness at First Relapse After Participation In First Line HOVON-49/50 Clinical Studies.
- First Posted Date
- 2007-02-27
- Last Posted Date
- 2015-04-16
- Lead Sponsor
- Janssen-Cilag B.V.
- Target Recruit Count
- 11
- Registration Number
- NCT00440479
Survey on the Treatment of Anemia Using Recombinant Human Erythropoietin 2 (STAR-2)
- First Posted Date
- 2006-11-14
- Last Posted Date
- 2012-11-06
- Lead Sponsor
- Janssen-Cilag B.V.
- Target Recruit Count
- 1927
- Registration Number
- NCT00398749
A Study of the Effectiveness and Safety of Treatment With Epoetin Alfa on Hemoglobin Levels, Red Blood Cell Transfusions, and Quality of Life in Patients With Cancer Receiving Platinum-containing Chemotherapy
- First Posted Date
- 2006-01-30
- Last Posted Date
- 2011-01-14
- Lead Sponsor
- Janssen-Cilag B.V.
- Target Recruit Count
- 316
- Registration Number
- NCT00283465
An Observational Study of Blood Management Techniques in Oncology Surgical Treatment
- First Posted Date
- 2005-12-12
- Last Posted Date
- 2014-04-28
- Lead Sponsor
- Janssen-Cilag B.V.
- Target Recruit Count
- 488
- Registration Number
- NCT00264095
Cost-effectiveness Study of Epoetin Alfa and Darbepoetin Alfa in Adult Patients With Cancer Who Have Anemia
- First Posted Date
- 2005-12-12
- Last Posted Date
- 2014-05-07
- Lead Sponsor
- Janssen-Cilag B.V.
- Target Recruit Count
- 492
- Registration Number
- NCT00264108
A Study of the Safety and Effectiveness of Epoetin Alfa on Hemoglobin Levels and Blood Transfusions in Cancer Patients Receiving Chemotherapy
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2011-05-19
- Lead Sponsor
- Janssen-Cilag B.V.
- Target Recruit Count
- 110
- Registration Number
- NCT00216541
© Copyright 2024. All Rights Reserved by MedPath